Zacks Investment Research
25 Jun 2026, 13:46 UTC · 20w ago
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
Impact · against what's priced in
AbCellera Biologics receives a moderate positive catalyst from a high-upside collaboration with Jazz Pharmaceuticals, though this is partially offset by expectations of a severe revenue contraction. BioMarin remains largely unaffected by the news.
- ABCL+0.30
No priced-in read yet





